{"DataElement":{"publicId":"6002274","version":"1","preferredName":"Chemotherapy Regimen Type","preferredDefinition":"A description of the chemotherapy regimen administered.","longName":"2014530v1.0:6002269v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2014530","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"the regimen of chemotherapy agents administered to the patient.","longName":"CT_RGM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177132","version":"1","preferredName":"Chemotherapy","preferredDefinition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.  Although this term may be used to describe any therapy involving the use of chemical-based agents, it is most commonly used to refer to the variety of chemical-based agents employed to treat cancer.  Cancer chemotherapy works by arresting or killing the growth and spread of cancer cells.  Because cancer cells usually divide much faster than normal cells, they are often very sensitive to the inhibitory actions of chemotherapeutic agents.  Chemotherapy may also include agents that enhance immune function or alter hormonal activity. (NCI04)","longName":"Chemotherapy","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A3D-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B940A4F5-33AA-0446-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-03-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6002269","version":"1","preferredName":"Chemotherapy Regimen Type","preferredDefinition":"Any regimen that can be used for the treatment of cancer._Something distinguishable as an identifiable class based on common qualities.","longName":"6002269v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"R-CVP","valueDescription":"R-CVP Regimen","ValueMeaning":{"publicId":"6002912","version":"1","preferredName":"R-CVP Regimen","longName":"6002912","preferredDefinition":"A regimen consisting of rituximab, cyclophosphamide, vincristine, and prednisone used to treat indolent non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CVP Regimen","conceptCode":"C63473","definition":"A regimen consisting of cyclophosphamide, vincristine, prednisone (CVP) and rituximab that may be used in the treatment of some forms of non-Hodgkin's lymphoma (NHL), including follicular lymphoma, gastric and nongastric MALT lymphomas, nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL), Castleman disease and post-transplant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E1D3-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E1EC-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"CVP","valueDescription":"CVP Regimen","ValueMeaning":{"publicId":"3366718","version":"1","preferredName":"CVP Regimen","longName":"3366718","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine and prednisone used to treat indolent forms of non-Hodgkin's lymphoma; also used for the treatment of chronic lymphocytic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CVP Regimen","conceptCode":"C9573","definition":"A regimen consisting of cyclophosphamide, vincristine and prednisone that may be used to treat Castleman disease, post-transplant lymphoproliferative disorders, indolent forms of non-Hodgkin lymphoma and chronic lymphocytic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-531B-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E1F6-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"CODOX-M","valueDescription":"CODOX-M Regimen","ValueMeaning":{"publicId":"6002914","version":"1","preferredName":"CODOX-M Regimen","longName":"6002914","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate used to treat aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment of AIDS-related and low-risk Burkitt's lymphoma. Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment of central nervous system (CNS) disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CODOX-M Regimen","conceptCode":"C63447","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate used to treat aggressive forms of non-Hodgkin lymphoma; also used as primary treatment of AIDS-related and low-risk Burkitt's lymphoma. Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment of central nervous system (CNS) disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E203-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E21C-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-CHOP","valueDescription":"R-CHOP Regimen","ValueMeaning":{"publicId":"6002915","version":"1","preferredName":"R-CHOP Regimen","longName":"6002915","preferredDefinition":"An immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOP Regimen","conceptCode":"C9760","definition":"A regimen consisting of cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine that may be used for the treatment of AIDS-related B-cell lymphomas, Castleman disease, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, gastric and nongastric MALT lymphomas, nodular lymphocyte-predominant Hodgkin lymphoma, mantle cell Lymphoma, nodal marginal zone lymphoma (NMZL), splenic marginal zone lymphoma (SMZL), Waldenstr√∂m macroglobulinemia and lymphoplasmacytic lymphoma, and post-transplant lymphoproliferative disorders.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E226-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E23F-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"CHOP","valueDescription":"CHOP Regimen","ValueMeaning":{"publicId":"3378205","version":"1","preferredName":"CHOP Regimen","longName":"3378205","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOP Regimen","conceptCode":"C9549","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine and prednisone that may be used to treat AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN), Castleman disease, primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, Hodgkin lymphoma and other non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9057ADC-737A-46E9-E040-BB89AD432383","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E249-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"BR","valueDescription":"BR Regimen","ValueMeaning":{"publicId":"6002916","version":"1","preferredName":"BR Regimen","longName":"6002916","preferredDefinition":"A regimen consisting of bendamustine and rituximab that can be used for the treatment of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BR Regimen","conceptCode":"C140094","definition":"A regimen consisting of bendamustine and rituximab that can be used for the treatment of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EB68A-E255-6286-E053-F662850A0582","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EB68A-E26E-6286-E053-F662850A0582","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"AVD + Brentuximab vedotin","valueDescription":"AVD Regimen And Brentuximab Vedotin","ValueMeaning":{"publicId":"6002910","version":"1","preferredName":"AVD Regimen And Brentuximab Vedotin","longName":"6002910","preferredDefinition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AVD Regimen","conceptCode":"C140093","definition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EA3D5-5443-6C81-E053-F662850A5B86","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"60116F76-DDEB-3ABF-E053-F662850AE0A4","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-12-11","modifiedBy":"ONEDATA","dateModified":"2017-12-11","deletedIndicator":"No"},{"value":"DeVIC","valueDescription":"DeVIC Regimen","ValueMeaning":{"publicId":"6002921","version":"1","preferredName":"DeVIC Regimen","longName":"6002921","preferredDefinition":"A regimen consisting of dexamethasone, etoposide, ifosfamide and carboplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DeVIC Regimen","conceptCode":"C140098","definition":"A regimen consisting of dexamethasone, etoposide, ifosfamide and carboplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7E60-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7E79-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"DHAP","valueDescription":"DHAP Regimen","ValueMeaning":{"publicId":"6002923","version":"1","preferredName":"DHAP Regimen","longName":"6002923","preferredDefinition":"A chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DHAP Regimen","conceptCode":"C63441","definition":"A chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7EA8-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7EC1-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-DHAP","valueDescription":"R-DHAP  Regimen","ValueMeaning":{"publicId":"6002922","version":"1","preferredName":"R-DHAP  Regimen","longName":"6002922","preferredDefinition":"A regimen consisting rituximab, dexamethasone, high dose cytarabine and cisplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-DHAP Regimen","conceptCode":"C140095","definition":"A regimen consisting rituximab, dexamethasone, high dose cytarabine and cisplatin that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7E85-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7E9E-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-DA-EPOCH","valueDescription":"R-DA-EPOCH  Regimen","ValueMeaning":{"publicId":"6002924","version":"1","preferredName":"R-DA-EPOCH  Regimen","longName":"6002924","preferredDefinition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose-adjusted EPOCH-R Regimen","conceptCode":"C140097","definition":"A regimen consisting of etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH-R) in a dose-adjusted (DA) version that can be used for the treatment of AIDS-related B-cell lymphomas, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7ECD-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7EE6-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"DA-EPOCH","valueDescription":"Dose Adjustment EPOCH Regimen","ValueMeaning":{"publicId":"6002926","version":"1","preferredName":"Dose Adjustment EPOCH Regimen","longName":"6002926","preferredDefinition":"An indication or description of a change in dosage.: A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Adjustment","conceptCode":"C82495","definition":"An indication or description of a change in dosage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"EPOCH Regimen","conceptCode":"C63779","definition":"A chemotherapy regimen consisting of etoposide, prednisone, vincristine (Oncovin), cyclophosphamide and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride), which may be used in combination with rituximab (R-EPOCH) for the treatment of various aggressive B cell and T cell non-Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7EF4-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7F0D-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"GemOx","valueDescription":"Gemcitabine-Oxaliplatin Regimen","ValueMeaning":{"publicId":"6002932","version":"1","preferredName":"Gemcitabine-Oxaliplatin Regimen","longName":"6002932","preferredDefinition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GemOx Regimen","conceptCode":"C64833","definition":"A regimen consisting of gemcitabine and oxaliplatin used for the treatment of biliary adenocarcinoma, pancreatic cancer, hepatocellular cancer and testicular cancer. This regimen is currently being studied in a variety of other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F1B-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7F34-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-GDP","valueDescription":"R-GDP Regimen","ValueMeaning":{"publicId":"6002933","version":"1","preferredName":"R-GDP Regimen","longName":"6002933","preferredDefinition":"A regimen consisting of rituximab, gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-GDP Regimen","conceptCode":"C140101","definition":"A regimen consisting of rituximab, gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F40-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7F59-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"GDP","valueDescription":"GDP Regimen","ValueMeaning":{"publicId":"6002934","version":"1","preferredName":"GDP Regimen","longName":"6002934","preferredDefinition":"A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GDP Regimen","conceptCode":"C140100","definition":"A regimen consisting of gemcitabine, dexamethasone and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F65-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7F7E-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-FCM","valueDescription":"R-FCM Regimen","ValueMeaning":{"publicId":"6002936","version":"1","preferredName":"R-FCM Regimen","longName":"6002936","preferredDefinition":"A regimen consisting of rituximab, fludarabine, cyclophosphamide and mitoxantrone used to treat indolent non-Hodgkin's lymphoma and relapsed or refractory mantle cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-FCM Regimen","conceptCode":"C63463","definition":"A regimen consisting of rituximab, fludarabine, cyclophosphamide and mitoxantrone used to treat indolent non-Hodgkin lymphoma and relapsed or refractory mantle cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7F8B-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7FA4-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-ESHAP","valueDescription":"R-ESHAP Regimen","ValueMeaning":{"publicId":"6002937","version":"1","preferredName":"R-ESHAP Regimen","longName":"6002937","preferredDefinition":"A regimen consisting of rituximab, etoposide, methylprednisolone, high-dose cytarabine and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-ESHAP Regimen","conceptCode":"C140099","definition":"A regimen consisting of rituximab, etoposide, methylprednisolone, high-dose cytarabine and cisplatin that can be used in the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7FB0-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7FC9-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"ESHAP","valueDescription":"ESHAP Regimen","ValueMeaning":{"publicId":"6002938","version":"1","preferredName":"ESHAP Regimen","longName":"6002938","preferredDefinition":"A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin's and non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ESHAP Regimen","conceptCode":"C63377","definition":"A regimen consisting of etoposide, methylprednisolone, high-dose cytarabine and cisplatin, used to treat relapsed and refractory Hodgkin and non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5ED270-7FD3-64D0-E053-F662850A8134","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5ED270-7FEC-64D0-E053-F662850A8134","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"BEACOPP, dose escalated","valueDescription":"Dose Escalation BEACOPP Regimen","ValueMeaning":{"publicId":"6002907","version":"1","preferredName":"Dose Escalation BEACOPP Regimen","longName":"6002907","preferredDefinition":"A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.: A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose Escalation","conceptCode":"C107213","definition":"A stepwise increase in the amount of a therapeutic or investigational agent given to an individual.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"BEACOPP Regimen","conceptCode":"C11638","definition":"A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EA3D5-53D1-6C81-E053-F662850A5B86","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EA3D5-53EA-6C81-E053-F662850A5B86","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"BEACOPP, standard","valueDescription":"Standard BEACOPP Regimen","ValueMeaning":{"publicId":"6002908","version":"1","preferredName":"Standard BEACOPP Regimen","longName":"6002908","preferredDefinition":"Regularly and widely used.: A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Standard","conceptCode":"C44275","definition":"Regularly and widely used.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"BEACOPP Regimen","conceptCode":"C11638","definition":"A chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone, used for the treatment of advanced-stage Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EA3D5-53F7-6C81-E053-F662850A5B86","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EA3D5-5410-6C81-E053-F662850A5B86","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-BAC","valueDescription":"R-BAC Regimen","ValueMeaning":{"publicId":"6002909","version":"1","preferredName":"R-BAC Regimen","longName":"6002909","preferredDefinition":"A regimen consisting of rituximab, bendamustine and cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-BAC Regimen","conceptCode":"C140111","definition":"A regimen consisting of rituximab, bendamustine and cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5EA3D5-541C-6C81-E053-F662850A5B86","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5EA3D5-5435-6C81-E053-F662850A5B86","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"VIPD","valueDescription":"VIPD Regimen","ValueMeaning":{"publicId":"6002982","version":"1","preferredName":"VIPD Regimen","longName":"6002982","preferredDefinition":"A regimen consisting of etoposide, ifosfamide, cisplatin and dexamethasone that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIPD Regimen","conceptCode":"C140114","definition":"A regimen consisting of etoposide, ifosfamide, cisplatin and dexamethasone that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5C56-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5C6F-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"SMILE","valueDescription":"SMILE Regimen","ValueMeaning":{"publicId":"6002983","version":"1","preferredName":"SMILE Regimen","longName":"6002983","preferredDefinition":"A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"SMILE Regimen","conceptCode":"C140113","definition":"A regimen consisting of dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide that can be used in the treatment of natural killer (NK)/T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5C7B-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5C94-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-Square","valueDescription":"R-Squared Regimen","ValueMeaning":{"publicId":"6002984","version":"1","preferredName":"R-Squared Regimen","longName":"6002984","preferredDefinition":"A regimen consisting of lenalidomide and rituximab that can be used in the treatment of follicular lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-Squared Regimen","conceptCode":"C140112","definition":"A regimen consisting of lenalidomide and rituximab that can be used in the treatment of primary central nervous system (CNS) lymphoma, Castleman disease, and non-Hodgkin lymphoma, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5CA0-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5CB9-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"Nordic regimen","valueDescription":"Nordic Regimen","ValueMeaning":{"publicId":"6002985","version":"1","preferredName":"Nordic Regimen","longName":"6002985","preferredDefinition":"A regimen consisting of cycles of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (Maxi-CHOP), alternating with rituximab with high-dose (HD) cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nordic Regimen","conceptCode":"C140110","definition":"A regimen consisting of cycles of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (Maxi-CHOP), alternating with rituximab with high-dose (HD) cytarabine that can be used in the treatment of mantle cell lymphoma (MCL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5CC5-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5CDE-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-MPV","valueDescription":"R-MPV Regimen","ValueMeaning":{"publicId":"6002986","version":"1","preferredName":"R-MPV Regimen","longName":"6002986","preferredDefinition":"A regimen consisting of rituximab, methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-MPV Regimen","conceptCode":"C140109","definition":"A regimen consisting of rituximab, methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5CEA-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D03-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"MPV","valueDescription":"MPV Regimen","ValueMeaning":{"publicId":"6002987","version":"1","preferredName":"MPV Regimen","longName":"6002987","preferredDefinition":"A regimen consisting of methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MPV Regimen","conceptCode":"C140108","definition":"A regimen consisting of methotrexate, procarbazine and vincristine that can be used in the treatment of central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5D0F-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D28-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"MRT","valueDescription":"MRT Regimen","ValueMeaning":{"publicId":"6002988","version":"1","preferredName":"MRT Regimen","longName":"6002988","preferredDefinition":"A regimen consisting of methotrexate, rituximab and temozolomide that can be used in the treatment of central nervous system (CNS) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MRT Regimen","conceptCode":"C140107","definition":"A regimen consisting of methotrexate, rituximab and temozolomide that can be used in the treatment of central nervous system (CNS) lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5D34-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D4D-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"MATRix","valueDescription":"MATRix Regimen","ValueMeaning":{"publicId":"6002989","version":"1","preferredName":"MATRix Regimen","longName":"6002989","preferredDefinition":"A regimen consisting of high-dose methotrexate, high-dose cytarabine, thiotepa and rituximab that can be used in the treatment of central nervous system (CNS) lymphoma and as a conditioning regimen for autologous stem cell transplantation (ASCT).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MATRix Regimen","conceptCode":"C140106","definition":"A regimen consisting of high-dose methotrexate, high-dose cytarabine, thiotepa and rituximab that can be used in the treatment of central nervous system (CNS) lymphoma and as a conditioning regimen for autologous stem cell transplantation (ASCT).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5D59-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D72-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"Stanford V","valueDescription":"Stanford V Regimen","ValueMeaning":{"publicId":"6002990","version":"1","preferredName":"Stanford V Regimen","longName":"6002990","preferredDefinition":"A chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule and used in the treatment of Hodgkin lymphoma; it may be followed by consolidative radiation therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stanford V Regimen","conceptCode":"C63369","definition":"A chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule and used in the treatment of Hodgkin lymphoma; it may be followed by consolidative radiation therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F1771-5D7C-53C3-E053-F662850A2F87","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D95-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"MOPP","valueDescription":"MOPP Regimen","ValueMeaning":{"publicId":"3379269","version":"1","preferredName":"MOPP Regimen","longName":"3379269","preferredDefinition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MOPP Regimen","conceptCode":"C9619","definition":"A chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91AC57E-1E84-187B-E040-BB89AD4329C2","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F1771-5D9F-53C3-E053-F662850A2F87","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"IVE","valueDescription":"IVE Regimen","ValueMeaning":{"publicId":"6002975","version":"1","preferredName":"IVE Regimen","longName":"6002975","preferredDefinition":"A regimen consisting of ifosfamide, epirubicin and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and as a stem cell mobilization regimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IVE Regimen","conceptCode":"C140105","definition":"A regimen consisting of ifosfamide, epirubicin and etoposide that can be used in the treatment of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and as a stem cell mobilization regimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FF4B-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089D-FF64-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-Hyper-CVAD alternating with R-cytarabine, methotrexate","valueDescription":"R-HyperCVAD/HD MTX AraC Regimen","ValueMeaning":{"publicId":"6002976","version":"1","preferredName":"R-HyperCVAD/HD MTX AraC Regimen","longName":"6002976","preferredDefinition":"A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, and alternating with rituximab, methotrexate and cytarabine that can be used for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL), as well as other types of lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-HyperCVAD Alternating with High-dose MTX AraC/Rituximab Regimen","conceptCode":"C140115","definition":"A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, and alternating with rituximab, and high-dose methotrexate and cytarabine that can be used for the treatment of mantle cell lymphoma (MCL), AIDS-related B-cell lymphomas, Burkitt lymphoma, chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL), as well as other types of lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FF74-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089D-FF8D-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-Hyper-CVAD","valueDescription":"R-Hyper-CVAD Regimen","ValueMeaning":{"publicId":"6002977","version":"1","preferredName":"R-Hyper-CVAD Regimen","longName":"6002977","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, plus rituximab that is used to treat some types of non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-Hyper-CVAD Regimen","conceptCode":"C140104","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, plus rituximab that is used to treat some types of non-Hodgkin lymphoma (NHL), including mantle cell lymphoma, and acute lymphoblastic leukemia (ALL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FF9B-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089D-FFB4-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"Hyper-CVAD","valueDescription":"HyperCVAD Regimen","ValueMeaning":{"publicId":"6002978","version":"1","preferredName":"HyperCVAD Regimen","longName":"6002978","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, used to treat adult L3 acute lymphoblastic leukemia (ALL3 or Burkitt's-type) and adult small non-cleaved cell (Burkitt's) lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Regimen","conceptCode":"C63455","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule that is used to treat adult acute lymphoblastic leukemia (ALL) or Burkitt-type ALL and adult small non-cleaved cell (Burkitt) lymphoma, AIDS-related B-cell lymphomas, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and T-cell lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FFC0-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089D-FFD9-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-HD-MTX / ARA-C","valueDescription":"R-HD-MTX/ARA-C Regimen","ValueMeaning":{"publicId":"6002979","version":"1","preferredName":"R-HD-MTX/ARA-C Regimen","longName":"6002979","preferredDefinition":"A regimen consisting of rituximab, high-dose (HD) methotrexate (MTX) and HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine/High-dose Methotrexate/Rituximab Regimen","conceptCode":"C140103","definition":"A regimen consisting of rituximab, high-dose (HD) methotrexate (MTX) and HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089D-FFE5-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089D-FFFE-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"HD-MTX / ARA-C","valueDescription":"HD-MTX/ARA-C Regimen","ValueMeaning":{"publicId":"6002980","version":"1","preferredName":"HD-MTX/ARA-C Regimen","longName":"6002980","preferredDefinition":"A regimen consisting of high-dose (HD) methotrexate (MTX) plus HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine/High-dose Methotrexate Regimen","conceptCode":"C140102","definition":"A regimen consisting of high-dose (HD) methotrexate (MTX) plus HD cytarabine (AraC) that can be used in the treatment of central nervous system (CNS) lymphoma and refractory or relapsed (RR) non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5F089E-000A-475C-E053-F662850A6912","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5F089E-0023-475C-E053-F662850A6912","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"FCM","valueDescription":"FCM Regimen","ValueMeaning":{"publicId":"6010533","version":"1","preferredName":"FCM Regimen","longName":"6010533","preferredDefinition":"A regimen consisting of fludarabine, cyclophosphamide and mitoxantrone that can be used in the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FCM Regimen","conceptCode":"C140730","definition":"A regimen consisting of fludarabine, cyclophosphamide and mitoxantrone that can be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8EDD-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8EF6-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"CODOX-M alternating with IVAC","valueDescription":"CODOX-M/IVAC Regimen","ValueMeaning":{"publicId":"3378652","version":"1","preferredName":"CODOX-M/IVAC Regimen","longName":"3378652","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) alternating with ifosfamide, etoposide and high-dose cytarabine (IVAC), used as a treatment for aggressive forms of non-Hodgkin's lymphoma; also used as primary treatment for AIDS-related and high-risk Burkitt's lymphoma.  Intrathecal cytarabine and methotrexate are included in this regimen as either prophylaxis or treatment for central nervous system (CNS) involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CODOX-M Alternating with IVAC Regimen","conceptCode":"C63448","definition":"A regimen that alternates cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (CODOX-M) with ifosfamide, etoposide and high-dose cytarabine (IVAC), and can be used in the treatment of Burkitt lymphoma and Burkitt-like lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9065DDB-F51E-EA21-E040-BB89AD43659B","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8F0A-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"R-CHOEP","valueDescription":"R-CHOPE Regimen","ValueMeaning":{"publicId":"6010534","version":"1","preferredName":"R-CHOPE Regimen","longName":"6010534","preferredDefinition":"A regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide that can be used in the treatment of non-Hodgkin lymphomas (NHL). R-CHOPE differs from R-EPOCH in the drug doses and schedule of the administration of the various drugs.\r\n\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOPE Regimen","conceptCode":"C140673","definition":"A regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and etoposide that can be used in the treatment of non-Hodgkin lymphomas (NHL). R-CHOPE differs from R-EPOCH in the drug doses and schedule of the administration of the various drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8F16-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8F2F-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"CHOEP","valueDescription":"CHOPE Regimen","ValueMeaning":{"publicId":"6010535","version":"1","preferredName":"CHOPE Regimen","longName":"6010535","preferredDefinition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide used to treat both indolent and aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CHOPE Regimen","conceptCode":"C9702","definition":"A regimen consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide that may be used to treat primary cutaneous CD30+ T-cell lymphoproliferative disorders, post-transplant lymphoproliferative disorders, T-cell lymphomas, and other forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8F3B-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8F54-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"R-CHOP alternating with R-DHAP","valueDescription":"R-CHOP/R-DHAP Regimen","ValueMeaning":{"publicId":"6010536","version":"1","preferredName":"R-CHOP/R-DHAP Regimen","longName":"6010536","preferredDefinition":"A regimen that alternates rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with rituximab, dexamethasone, high-dose cytarabine and cisplatin (R-DHAP), and can be used in the treatment of mantle cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-CHOP Alternating with R-DHAP Regimen","conceptCode":"C140734","definition":"A regimen that alternates rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with rituximab, dexamethasone, high-dose cytarabine and cisplatin (R-DHAP), and can be used in the treatment of mantle cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8F60-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8F79-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"BAC","valueDescription":"BAC Regimen","ValueMeaning":{"publicId":"6010537","version":"1","preferredName":"BAC Regimen","longName":"6010537","preferredDefinition":"A regimen consisting of bendamustine and cytarabine that can be used in the treatment of mantle-cell lymphoma (MCL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BAC Regimen","conceptCode":"C140657","definition":"A regimen consisting of bendamustine and cytarabine that can be used in the treatment of mantle-cell lymphoma (MCL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8F85-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8F9E-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"R-ACVBP","valueDescription":"R-ACVBP Regimen","ValueMeaning":{"publicId":"6010538","version":"1","preferredName":"R-ACVBP Regimen","longName":"6010538","preferredDefinition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone and rituximab that can be used in the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-ACVBP Regimen","conceptCode":"C140658","definition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone and rituximab that can be used in the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64899D-8FAA-5E4E-E053-F662850AF522","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64899D-8FC3-5E4E-E053-F662850AF522","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"ACVBP","valueDescription":"LNH-87","ValueMeaning":{"publicId":"3366707","version":"1","preferredName":"LNH-87","longName":"3366707","preferredDefinition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ACVBP Regimen","conceptCode":"C63446","definition":"A regimen consisting of doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone used to treat aggressive forms of non-Hodgkin lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-51F8-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5A5F30-7D2B-7D6E-E053-F662850AC99A","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"AVD","valueDescription":"AVD Regimen","ValueMeaning":{"publicId":"6002270","version":"1","preferredName":"AVD Regimen","longName":"6002270","preferredDefinition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AVD Regimen","conceptCode":"C140093","definition":"A regimen consisting of doxorubicin, vinblastine and dacarbazine that can be used for the treatment of Hodgkin lymphoma (HL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CD9-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"COOPERM","dateModified":"2020-12-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5A5F30-7CF2-7D6E-E053-F662850AC99A","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"AspaMetDex","valueDescription":"AspaMetDex Regimen","ValueMeaning":{"publicId":"6002271","version":"1","preferredName":"AspaMetDex Regimen","longName":"6002271","preferredDefinition":"A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AspaMetDex Regimen","conceptCode":"C140092","definition":"A regimen consisting of L-asparaginase, methotrexate and dexamethasone that can be used for the treatment of non-Hodgkin lymphoma (NHL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CFE-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5A5F30-7D17-7D6E-E053-F662850AC99A","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"ABVD","valueDescription":"ABVD Regimen","ValueMeaning":{"publicId":"3377419","version":"1","preferredName":"ABVD Regimen","longName":"3377419","preferredDefinition":"A chemotherapy regimen consisting of doxorubicin hydrochloride (Adriamycin), bleomycin, vinblastine and dacarbazine, used alone or in combination with radiation therapy, for the primary treatment of Hodgkin lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ABVD Regimen","conceptCode":"C9509","definition":"A regimen consisting of doxorubicin, bleomycin, vinblastine and dacarbazine that can be used in the treatment of Hodgkin lymphoma (HL).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C13-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B5A5F30-7D35-7D6E-E053-F662850AC99A","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","deletedIndicator":"No"},{"value":"R-ICE","valueDescription":"R-ICE Regimen","ValueMeaning":{"publicId":"6010539","version":"1","preferredName":"R-ICE Regimen","longName":"6010539","preferredDefinition":"A chemoimmunotherapy regimen consisting of rituximab, ifosfamide, carboplatin and etoposide used to treat indolent and aggressive forms of non-Hodgkin's lymphoma; also used to treat relapsed and refractory non-Hodgkin's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-ICE Regimen","conceptCode":"C63465","definition":"A regimen consisting of rituximab, ifosfamide, carboplatin and etoposide that can be used for the treatment of nodular lymphocyte-predominant Hodgkin lymphoma and certain forms of non-Hodgkin lymphoma (NHL), such as Burkitt lymphoma and diffuse large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-38C5-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-38DE-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"ICE","valueDescription":"ICE Regimen","ValueMeaning":{"publicId":"3366711","version":"1","preferredName":"ICE Regimen","longName":"3366711","preferredDefinition":"A chemotherapy regimen consisting of ifosfamide, carboplatin and etoposide used in the treatment of relapsed and refractory non-Hodgkin and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ICE Regimen","conceptCode":"C10345","definition":"A regimen consisting of carboplatin, etoposide and ifosfamide that can be used in the treatment of non-Hodgkin and Hodgkin lymphomas, including diffuse large B-cell lymphoma and T-cell lymphoma, mycosis fungoides/Sezary syndrome, and gestational trophoblastic neoplasia. Paclitaxel/carboplatin/oral etoposide regimen can be used for the treatment of occult primary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C1BF06-5264-30E6-E040-BB89AD436407","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-38E8-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"Hyper-CVAD alternating with cytarabine, methotrexate","valueDescription":"HyperCVAD/HD MTX AraC Regimen","ValueMeaning":{"publicId":"6010540","version":"1","preferredName":"HyperCVAD/HD MTX AraC Regimen","longName":"6010540","preferredDefinition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone (Hyper-CVAD) administered on a hyperfractionated schedule, followed by high dose methotrexate and cytarabine, and used to treat Burkitt's lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"HyperCVAD Alternating with High-dose MTX AraC Regimen","conceptCode":"C63472","definition":"A regimen consisting of cyclophosphamide, vincristine, doxorubicin and dexamethasone, administered on a hyperfractionated schedule, alternating with high-dose cytarabine and methotrexate, that can be used in the treatment of acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-38F4-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-390D-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"R-GVD","valueDescription":"R-GVD Regimen","ValueMeaning":{"publicId":"6010541","version":"1","preferredName":"R-GVD Regimen","longName":"6010541","preferredDefinition":"A regimen consisting of rituximab, gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-GVD Regimen","conceptCode":"C140733","definition":"A regimen consisting of rituximab, gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-3919-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-3932-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"GVD","valueDescription":"GVD Regimen","ValueMeaning":{"publicId":"6010542","version":"1","preferredName":"GVD Regimen","longName":"6010542","preferredDefinition":"A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin that can be used in the treatment of Hodgkin lymphoma (HL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"GVD Regimen","conceptCode":"C140732","definition":"A regimen consisting of gemcitabine, vinorelbine and pegylated liposomal doxorubicin used for the treatment of Hodgkin lymphoma (HL), T-cell lymphomas, and mycosis fungoides and Sezary syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-393E-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-3957-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"R-GemOx","valueDescription":"R-GemOx Regimen","ValueMeaning":{"publicId":"6010543","version":"1","preferredName":"R-GemOx Regimen","longName":"6010543","preferredDefinition":"A regimen consisting of rituximab, gemcitabine and oxaliplatin that can be used in the treatment of diffuse large B-cell lymphoma (DLBCL).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"R-GemOx Regimen","conceptCode":"C140731","definition":"A regimen consisting of rituximab, gemcitabine and oxaliplatin used in the treatment of diffuse large B-cell lymphoma (DLBCL).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5C64ADD9-3963-3F16-E053-F662850A65BD","latestVersionIndicator":"Yes","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5C64ADD9-397C-3F16-E053-F662850A65BD","beginDate":"2017-10-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-25","modifiedBy":"ONEDATA","dateModified":"2017-10-25","deletedIndicator":"No"},{"value":"RD","valueDescription":"Lenalidomide-Dexamethasone Regimen","ValueMeaning":{"publicId":"6025018","version":"1","preferredName":"Lenalidomide-Dexamethasone Regimen","longName":"6025018","preferredDefinition":"A regimen consisting of lenalidomide and dexamethasone used to treat relapsed or refractory multiple myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone/Lenalidomide Regimen","conceptCode":"C64732","definition":"A regimen consisting of lenalidomide and dexamethasone that can be used in the treatment of plasma cell myeloma and systemic light chain amyloidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C34D-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80204286-000A-301C-E053-F662850A98EA","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"DVD / VDD","valueDescription":"Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen","ValueMeaning":{"publicId":"6025019","version":"1","preferredName":"Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen","longName":"6025019","preferredDefinition":"A treatment regimen consisting of a combination of bortezomib, dexamethasone and pegylated liposomal doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib/Dexamethasone/Pegylated Liposomal Doxorubicin Regimen","conceptCode":"C113828","definition":"A regimen consisting of bortezomib, dexamethasone and pegylated liposomal doxorubicin that can be used in the treatment of plasma cell (multiple) myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C370-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80204286-0014-301C-E053-F662850A98EA","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"RVD / VRD","valueDescription":"Bortezomib/Dexamethasone/Lenalidomide Regimen","ValueMeaning":{"publicId":"6025020","version":"1","preferredName":"Bortezomib/Dexamethasone/Lenalidomide Regimen","longName":"6025020","preferredDefinition":"A treatment regimen consisting of a combination of bortezomib, dexamethasone and lenalidomide.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RVD Regimen","conceptCode":"C113827","definition":"A regimen consisting of bortezomib, dexamethasone and lenalidomide that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C393-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80204286-001E-301C-E053-F662850A98EA","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"VCD","valueDescription":"Bortezomib/Cyclophosphamide/Dexamethasone Regimen","ValueMeaning":{"publicId":"6025021","version":"1","preferredName":"Bortezomib/Cyclophosphamide/Dexamethasone Regimen","longName":"6025021","preferredDefinition":"A treatment regimen consisting of a combination of bortezomib, cyclophosphamide and dexamethasone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib/Cyclophosphamide/Dexamethasone Regimen","conceptCode":"C113826","definition":"A regimen consisting of bortezomib, cyclophosphamide and dexamethasone that can be used in the treatment of plasma cell (multiple) myeloma and systemic light chain amyloidosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C3B6-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"80204286-0028-301C-E053-F662850A98EA","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"ONEDATA","dateModified":"2019-01-23","deletedIndicator":"No"},{"value":"KRD","valueDescription":"Carfilzomib/Lenalidomide/Dexamethasone Regimen","ValueMeaning":{"publicId":"6782321","version":"1","preferredName":"Carfilzomib/Lenalidomide/Dexamethasone Regimen","longName":"6782321","preferredDefinition":"A chemotherapy regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"KRd Regimen","conceptCode":"C136264","definition":"A regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell (multiple) myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B84AC14-DF47-66B8-E053-F662850AE1C8","latestVersionIndicator":"Yes","beginDate":"2019-06-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-17","modifiedBy":"ONEDATA","dateModified":"2019-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B84AC14-DF60-66B8-E053-F662850AE1C8","beginDate":"2019-06-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-17","modifiedBy":"ONEDATA","dateModified":"2019-06-17","deletedIndicator":"No"},{"value":"DVD","valueDescription":"Daratumumab/Bortezomib/Dexamethasone Regimen","ValueMeaning":{"publicId":"6782323","version":"1","preferredName":"Daratumumab/Bortezomib/Dexamethasone Regimen","longName":"6782323","preferredDefinition":"A chemoimmunotherapy regimen consisting of daratumumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dara-Vd Regimen","conceptCode":"C136267","definition":"A  regimen consisting of daratumumab, bortezomib and dexamethasone that is used for the treatment of plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B84AC14-DF6D-66B8-E053-F662850AE1C8","latestVersionIndicator":"Yes","beginDate":"2019-06-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-17","modifiedBy":"ONEDATA","dateModified":"2019-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B84AC14-DF86-66B8-E053-F662850AE1C8","beginDate":"2019-06-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-06-17","modifiedBy":"ONEDATA","dateModified":"2019-06-17","deletedIndicator":"No"},{"value":"ITT","valueDescription":"Cytarabine/Hydrocortisone/Methotrexate Regimen Intrathecal Route of Administration","ValueMeaning":{"publicId":"7092722","version":"1","preferredName":"Cytarabine/Hydrocortisone/Methotrexate Regimen Intrathecal Route of Administration","longName":"7092722","preferredDefinition":"A chemotherapy regimen consisting of cytarabine, hydrocortisone, and methotrexate that may be used in the treatment and prevention of central nervous system (CNS) involvement in leukemias and lymphomas.: Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine/Hydrocortisone/Methotrexate Regimen","conceptCode":"C10201","definition":"A regimen consisting of cytarabine, hydrocortisone, and methotrexate that may be used in the treatment and prevention of central nervous system (CNS) involvement in leukemias and lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0A1E-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0A37-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"IT cytarabine alone","valueDescription":"Single Cytarabine Intrathecal Route of Administration","ValueMeaning":{"publicId":"7092723","version":"1","preferredName":"Single Cytarabine Intrathecal Route of Administration","longName":"7092723","preferredDefinition":"Not accompanied by another or others; exclusive of anyone or anything else.: An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04): Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0A45-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0A5E-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"IT cytarabine / hydrocortisone","valueDescription":"Cytarabine And Therapeutic Hydrocortisone Intrathecal Route of Administration","ValueMeaning":{"publicId":"7092724","version":"1","preferredName":"Cytarabine And Therapeutic Hydrocortisone Intrathecal Route of Administration","longName":"7092724","preferredDefinition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04): An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04): Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapeutic Hydrocortisone","conceptCode":"C555","definition":"A synthetic or semisynthetic analog of natural hydrocortisone hormone produced by the adrenal glands with primary glucocorticoid and minor mineralocorticoid effects. As a glucocorticoid receptor agonist, hydrocortisone promotes protein catabolism, gluconeogenesis, capillary wall stability, renal excretion of calcium, and suppresses immune and inflammatory responses. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intrathecal Route of Administration","conceptCode":"C38267","definition":"Administration of drugs directly into spinal subarachnoid space in the cerebrospinal fluid, at any level of the cerebrospinal axis, including injection into the cerebral ventricles, in order to bypass the blood-brain barrier and achieve local, rapid effects on the meninges or cerebrospinal axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D6ADE6-0A6D-743B-E053-F662850A05E5","latestVersionIndicator":"Yes","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0A86-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6424136","version":"1","preferredName":"Other","longName":"6424136","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"753441A1-068C-5A23-E053-F662850A6B7A","latestVersionIndicator":"Yes","beginDate":"2018-09-06","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2018-09-06","modifiedBy":"KUMMEROA","dateModified":"2023-02-02","changeDescription":null,"administrativeNotes":"2023.2.2 Alt VM added per ticket request CADSR0002006. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"99D6ADE6-0A90-743B-E053-F662850A05E5","beginDate":"2019-12-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-12-16","modifiedBy":"ONEDATA","dateModified":"2019-12-16","deletedIndicator":"No"},{"value":"Regimen VIVA","valueDescription":"VIVA Regimen","ValueMeaning":{"publicId":"7343392","version":"1","preferredName":"VIVA Regimen","longName":"7343392","preferredDefinition":"A chemotherapy regimen consisting of dactinomycin, irinotecan and vincristine that may be used in the treatment of Wilms tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIVA Regimen","conceptCode":"C173101","definition":"A chemotherapy regimen consisting of dactinomycin, irinotecan and vincristine that may be used in the treatment of Wilms tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA2BD5-C4D7-331E-E053-4EBD850AD2E8","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C4F0-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"},{"value":"Regimen MVI","valueDescription":"MVI Regimen","ValueMeaning":{"publicId":"7343393","version":"1","preferredName":"MVI Regimen","longName":"7343393","preferredDefinition":"A chemotherapy regimen that is similar to regimen M, consisting of vincristine, dactinomycin and doxorubicin plus cyclophosphamide and etoposide, but in which some of the high-dose cyclophosphamide and etoposide cycles are replaced by vincristine and irinotecan to minimize toxicity and that may be used in the treatment of Wilms tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"MVI Regimen","conceptCode":"C173100","definition":"A chemotherapy regimen that is similar to regimen M, consisting of vincristine, dactinomycin and doxorubicin plus cyclophosphamide and etoposide, but in which some of the high-dose cyclophosphamide and etoposide cycles are replaced by vincristine and irinotecan to minimize toxicity and that may be used in the treatment of Wilms tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA2BD5-C4FC-331E-E053-4EBD850AD2E8","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C515-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"},{"value":"Regimen M","valueDescription":"Cyclophosphamide/Etoposide Regimen","ValueMeaning":{"publicId":"7343395","version":"1","preferredName":"Cyclophosphamide/Etoposide Regimen","longName":"7343395","preferredDefinition":"A chemotherapy regimen consisting of high-dose cyclophosphamide and etoposide that may be used in the treatment of refractory acute myeloid leukemia (AML).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide/Etoposide Regimen","conceptCode":"C9713","definition":"A chemotherapy regimen consisting of high-dose cyclophosphamide and etoposide that may be used in the treatment of refractory acute myeloid leukemia (AML).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA2BD5-C522-331E-E053-4EBD850AD2E8","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C53B-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"},{"value":"VAD","valueDescription":"VAD Regimen","ValueMeaning":{"publicId":"3380357","version":"1","preferredName":"VAD Regimen","longName":"3380357","preferredDefinition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for multiple myeloma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VAD Regimen","conceptCode":"C63498","definition":"A regimen consisting of vincristine, doxorubicin and dexamethasone used as induction treatment for plasma cell myeloma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6F0-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C545-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"},{"value":"DD4A","valueDescription":"DD-4A Regimen","ValueMeaning":{"publicId":"7343397","version":"1","preferredName":"DD-4A Regimen","longName":"7343397","preferredDefinition":"A regimen consisting of vincristine, dactinomycin and doxorubicin, administered on a pulse-intensive dosing schedule, given in combination with radiation therapy following nephrectomy and used as a treatment for clear cell sarcoma of the kidney (CCSK) as well as advanced-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DD-4A Regimen","conceptCode":"C67303","definition":"A regimen consisting of vincristine, dactinomycin and doxorubicin, administered on a pulse-intensive dosing schedule, given in combination with radiation therapy following nephrectomy and used as a treatment for clear cell sarcoma of the kidney (CCSK) as well as advanced-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA2BD5-C552-331E-E053-4EBD850AD2E8","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C56B-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"},{"value":"EE4A","valueDescription":"EE-4A Regimen","ValueMeaning":{"publicId":"7343399","version":"1","preferredName":"EE-4A Regimen","longName":"7343399","preferredDefinition":"A regimen consisting of vincristine and dactinomycin, administered after nephrectomy and used for the treatment of limited-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"EE-4A Regimen","conceptCode":"C67293","definition":"A regimen consisting of vincristine and dactinomycin, administered after nephrectomy and used for the treatment of limited-stage Wilm's tumor with a favorable histology, including focal anaplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A8EA2BD5-C578-331E-E053-4EBD850AD2E8","latestVersionIndicator":"Yes","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A8EA2BD5-C591-331E-E053-4EBD850AD2E8","beginDate":"2020-06-25","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-06-25","modifiedBy":"ONEDATA","dateModified":"2020-06-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435016","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B9F7-9264-25C9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6002268","version":"1","preferredName":"Chemotherapy Regimen Type","preferredDefinition":"Any regimen that can be used for the treatment of cancer.:Something distinguishable as an identifiable class based on common qualities.","longName":"C62634:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemo/immuno/hormone Therapy Regimen","conceptCode":"C62634","definition":"Any regimen that can be used for the treatment of cancer and non-neoplastic disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CB0-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"ONEDATA","dateModified":"2017-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7CC1-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"MALUMK","dateModified":"2020-06-29","changeDescription":". Added PVs for 2016r4. AK 6/17/19 PVs added for another context. AK 2019-12-16. PVs added for context Children¬ís Oncology Group. 06/25/2020 KMM. ALT Names added for Children's Oncology Group. 06/29/2020 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"LYMpre_thrpym_drug_regimen_ty","type":"NMDP_FN","context":"NHLBI"},{"name":"ITT_TX","type":"COG GDE Short Name","context":"COG"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"What was the chemotherapy reg","type":"Preferred Question Text","description":"What was the chemotherapy regimen?","url":null,"context":"NHLBI"},{"name":"Specify regimen","type":"Alternate Question Text","description":"Specify regimen","url":null,"context":"NHLBI"},{"name":"Specify regimen","type":"Application Standard Question Text","description":"Specify regimen","url":null,"context":"NHLBI"},{"name":"COG CRF TEXT 1","type":"Alternate Question Text","description":"Which intrathecal therapy was given during this reporting period?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Regimen Name","url":null,"context":"COG"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B5A5F30-7D48-7D6E-E053-F662850AC99A","latestVersionIndicator":"Yes","beginDate":"2017-10-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-10-12","modifiedBy":"GALITG","dateModified":"2020-06-26","changeDescription":".; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}